Nanobodies are single-domain antibodies derived from mammalian heavy-chain antibodies, with unique properties such as nanosized, robust structure, stable and soluble behavior in aqueous solutions and reversible protein refolding among others. Furthermore, the increasing prevalence of chronic diseases, rising demand for precision medicine, and increasing investment in nanobody research and development are further expected to drive the growth of the global nanobody market during the forecast period. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their devices and signing contracts and agreements to broaden their reach and reduce operational costs. For instance, in August 2020, Beroni Group Limited (Australia) announced a collaboration agreement with Genscript Biotech Corporation (US) for the development of a medical solution utilizing nanobody technology for COVID-19, particularly in leading pseudovirus neutralization test, humanization, and affinity maturation of nanobodies with the impartial of increasing the antibody affinity to target the antigen by five to ten-fold.
The global nanobody market is extremely competitive, with players competing, partnering, and investing heavily in R&D to gain a significant market share. The market is moderately fragmented with rising competition, increasing collaborative partnerships, and other strategic decisions to achieve operational efficiency.
The business model developed by manufacturers in the global nanobody market includes manufacturing advanced nanobody drugs. The growth of prominent industry players is dependent on various factors, such as market conditions, government support, and industry development. Key manufacturers of nanobodies are also focusing on investing in R&D activities. This will boost market growth in the upcoming future.
With respect to the current scope of the report, Sanofi (France) is the top player in the global nanobody market due to its strong product offering and high preference for its products by customers. Merck KGaA (Germany) is the second major player, followed by Novartis AG (Switzerland), Taisho Pharmaceutical Holdings Co Ltd (Japan), and Beroni Group (Australia). Other key players contributing to the market growth include BIOCYTOGEN (US), Proteintech Group, Inc. (US), GenScript (US), Sensei Biotherapeutics, Inc (US), ExeVir Bio (Belgium), and Dioscure Therapeutics SE (Germany).
Threat of New Entrants
The threat of new entrants is moderate in the global nanobody market due to the development of the potential market. Any nanobody manufacturing company trying to enter the market is required to accept and abide by the mandatory regulatory standards set by the respective regulatory authorities of the country, such as the United States Food and Drug Administration (FDA), The European Medicines Agency (EMA), The Central Drugs Standard Control Organisation (CDSCO), and others. The growing development of new applications of nanobodies pushes the currently established and other manufacturers to focus more on adopting innovative technologies. There is a stronghold of the big companies in this market, which can make the entry of new players challenging. Thus, the threat of new entrants in the market is moderate.
Bargaining Power of Suppliers
The suppliers in the nanobody market are the developers and manufacturers of nanobodies used for treating chronic diseases and diagnostics. The bargaining power of suppliers is a crucial factor in the nanobody market and determines the industry's strength. Many suppliers are currently present in the market due to the availability of a huge patient pool, high demand for treatment, and increasing government support. The existing key companies capture significant market share and monitor the cost of the drugs. The switching cost of these suppliers is moderate because suppliers tend to enter long-term associations, partnerships, and deals with other drug manufacturing companies. Thus, the overall bargaining power of suppliers in the nanobody market is expected to be moderate during the forecast period.
Threat of Substitutes
The threat of substitutes in the global nanobody market is moderate to high. Nanobodies offer several advantages over traditional biologics, such as their small size and high stability among others, the market may face competition from traditional monoclonal antibodies and gene therapy in current times. However, the unique properties of nanobodies, such as their ability to penetrate tissue and cross the blood-brain barrier, may give them an advantage over these substitutes in certain applications.
Bargaining Power of Buyers
The nanobody market is characterized by the presence of a large number of buyers. The market for nanobodies is identified as having a significant customer base, considering the increasing number of patients suffering from chronic diseases such as autoimmune diseases, blood disorders, and others. However, the buyers tend to use the products that have been provided by the top players, as currently there are very limited numbers of players operating in the nanobody market. Thus, the bargaining power of buyers is expected to be low in the nanobody market during the forecast period.
Intensity of Rivalry
The degree of competition in the global nanobody market is high, owing to the presence of a large number of prominent players. Moderate product differentiation among existing players increases the intensity of rivalry in the market. Nanobody manufacturing companies are developing advanced products for differentiating their brand from competitors. Additionally, many prominent market players are entering into strategic partnerships, co-development activities, and tie-ups with established companies to overcome the competition. Thus, the intensity of rivalry in the global nanobody market is expected to be high during the study period.
